Johnson & Johnson (JNJ), a global healthcare leader, has announced that they are exploring a
$20 billion potential sale of its Orthopedics Unit - DePuy Synthes. Concurrently, they have announced
$1 billion investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania, which will create 500 new jobs. This strategic move may result in moving out of orthopedics and focusing on cell therapy, which can be seen as aligning the company towards more innovative and potentially high-value market segments. Despite some fluctuating stock positions and legal issues concerning talc, the company shows a promising future by being awarded
the FDA's breakthrough status for its Advanced Head and Neck Cancer drug and receiving an
upgrade in dividends.
John Morikis, a retired executive of The Sherwin-Williams Company, was recently elected to J&J's Board of Directors. Additionally, they have announced new long-term data from Quasar Long-Term Extension Study. The company was named
one of 2026 Fortune World's Most Admired Companies.
Johnson Johnson JNJ News Analytics from Wed, 18 Jun 2025 10:34:37 GMT to Sat, 21 Feb 2026 20:03:10 GMT -
Rating 8
- Innovation 9
- Information 7
- Rumor -5
